Table 1 Summary of clinical characteristics and laboratory variables

Patient (n)

401

Female sex (n (%))

134 (33)

Age (years)

68 ± 13

Body mass index (Kg/m²)

28.4 (6.3)

Smoking history (n (%))

48 (12)

COVID-19 severity (WHO category) (n (%))

 • Mild/moderate

150 (37.4)

 • Severe

142 (35.4)

 • Critical

109 (27.2)

Comorbidities (n (%)):

 • Hypertension

221 (55)

 • Chronic kidney disease

110 (27)

 • Diabetes

81 (20)

 • Active neoplasia

59 (15)

 • COPD

25 (6.2)

 • Autoimmune disease

23 (5.7)

 • Cirrhosis

20 (5.0)

 Pulmonary embolism (n (%))

109 (27)

 Intensive care unit admission (n (%))

74 (19)

 Orotracheal intubation (n (%))

64 (16)

 In-hospital death (n (%))

79 (20)

 Median follow-up time (days)

8 [5–17]

Vital sign

 Body temperature (°C)

36.8 ± 0.7

 Respiratory rate (breaths per minute)

21 ± 5

 Arterial oxygen saturation (%)

95 [92–97]

 Systolic blood pressure (mm Hg)

135 ± 21

 Heart rate (bpm)

83 (15)

Biochemical variable or biomarker

 Hemoglobin (g/dl)

13.0 ± 1.9

 WBC (cells × 10³/mm³)

7.20 [5.14–10.53]

 Lymphocytes (cells × 10³/mm³)

0.80 [0.50–1.08]

 Platelets (cells × 10³/mm³)

233 [183–321]

 CRP (mg/l)

62 [28–111]

 D-dimer (ng/dl FEU)

1000 [560–3120]

 eGFR (ml/min/1.73m²)

78 ± 31

Drug

 ACEi/ARB (n (%))

139 (35)

 Statin (n (%))

88 (22)

 Antiplatelet (n (%))

85 (21)

 Any heparin use (n (%))

339 (85)